A Phase 3 interventional study of BXCL501 and Matching Placebo in Agitation,Psychomotor, Bipolar I Disorder and Bipolar II Disorder, sponsored by BioXcel Therapeutics Inc. Completed at 24 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by BioXcel Therapeutics Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing dexmedetomidine in Psychomotor Agitation — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Psychomotor Agitation.
Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, this one has the largest enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 24th registered.
231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.
Browse Psychomotor Agitation studies →5 of the 32 studies testing dexmedetomidine in Psychomotor Agitation are open now, in 3 countries. Recruiting first, the newest first:
Lone Baandrup · Sites in Denmark
Ages 18–64
Temple University · Sites in United States
Ages 18–55
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Benha University
Ages 18+
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Ages 18+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 11
First in 2005; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 452 is above the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.
Median enrollment 73 across the 32 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
11 studies in Psychomotor Agitation by BioXcel Therapeutics Inc: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Psychomotor Agitation by BioXcel Therapeutics Inc, this one has the largest enrollment, is one of 4 that started in 2022, is one of 5 in phase 3, and was the 8th registered.
BioXcel Therapeutics Inc’s Psychomotor Agitation studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, from their registry updates:
Among BioXcel Therapeutics Inc’s 11 in Psychomotor Agitation:
This tab as a report to print or save as PDF → With an account.
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
This is a randomized, double-blind, placebo-controlled, 2-Part, Phase III study to assess the efficacy, safety, and tolerability of BXCL501 in adult (18-75 years old) males and females with agitation episodes associated with a primary diagnosis of bipolar I disorder, bipolar II disorder, schizophrenia, schizoaffective disorder, or schizophreniform disorder. Part 1 of the study is a one-day, in-clinic treatment of 60 mcg dose, and post-treatment observation period with patients experiencing an acute episode of agitation. Part 1 is now complete. Part 2 of the study is a 12-week study to determine the safety of a BXCL501 120 mcg dose when used as needed for episodes of agitation at home.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient may enroll in only one part of the study; either Part 1 or Part 2.
Inclusion Criteria:
Part 1 only
Part 2 only
Exclusion Criteria:
Part 1 only
Part 2 only
Informant Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sublingual film containing 60 Micrograms Dexmedetomidine
Drug: BXCL501
Sublingual Placebo film
Drug: Matching Placebo
Sublingual film containing 120 Micrograms Dexmedetomidine
Drug: BXCL501
Sublingual Placebo film
Drug: Matching Placebo
Sublingual Film
Also known as: Dexmedetomidine
Sublingual Placebo Film
Also known as: Placebo
Part 1: Change from baseline in Positive and Negative Syndrome Scale - Excited (PEC) total score
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)
Time frame: 2 hours
Part 2: The incidence of SAEs and TEAEs compared with placebo.
To assess the safety of 120 mcg BXCL501 when used in an at-home environment based on serious adverse events (SAE) and treatment emergent adverse events (TEAEs).
Time frame: Through study completion, an average of 12 weeks
Part 1: Clinical Global Impression - Improvement (CGI-I)
The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.
Time frame: 2 hours
Part 1: Change in Modified Clinical Global Impression - Severity (mCGI-S) scores from Baseline
The Modified Clinical Global Impression - Severity (mCGI-S) measures the current level of agitation. For this study, the mCGI-S is a 4-point scale where a score of 0 represents no agitation, and scores of 1-3 describe increasing severities of agitation (mild, moderate, severe).
Time frame: 2 hours
Part 1:The number of responders based on the Modified Clinical Global Impression - Severity (mCGI-S) score
The Modified Clinical Global Impression - Severity (mCGI-S) measures the current level of agitation. A responder is characterized as a participant with a score of 0 (represents no agitation) or 1 (mild agitation)
Time frame: 2 hours
Part 1:Change from baseline in Agitation-Calmness Evaluation Scale (ACES)
The Agitation-Calmness Evaluation Scale (ACES) is a single item scale that measures overall agitation and sedation, where a score of 1 indicates marked agitation; 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable.
Time frame: 2 hours
Part 1: Incidence of treatment-emergent adverse events (TEAEs)
To assess the safety of BXCL501 based on treatment-emergent adverse events (TEAEs)
Time frame: Through study completion, an average of 8 hours
Part 1: Change from baseline in heart rate (HR) at rest
The effect of BXCL501 on heart rate at rest
Time frame: Baseline, and 2, 4, 6, and 8 hours postdose
Part 1: Change from baseline in heart rate (HR) under orthostatic stress
The effect of BXCL501 on heart rate under orthostatic stress
Time frame: Baseline, and 2, 4, 6, and 8 hours postdose
Part 1: Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at rest
The effect of BXCL501 on systolic and diastolic blood pressure at rest
Time frame: Baseline, and 2, 4, 6, and 8 hours postdose
Part 1: Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) under orthostatic stress
The effect of BXCL501 on systolic and diastolic blood pressure under orthostatic stress
Time frame: Baseline, and 2, 4, 6, and 8 hours postdose
Part 1: Incidence of abnormal electrocardiograms (ECG) reported as an adverse event (AE)
Any abnormal ECG value that is reported as an adverse event (AE)
Time frame: Through study completion, an average of 8 hours
Part 1: Incidence of abnormal clinical laboratory values reported as an adverse event (AE)
Any abnormal clinical laboratory value that is reported as an adverse event (AE)
Time frame: Through study completion, an average of 8 hours
Part 2: Incidence of interactions with emergency services related to agitation
Evaluate the impact of BXCL501 on the use of healthcare and emergency service resources because of agitation episodes
Time frame: Through study completion, an average of 12 weeks
Part 2: Incidence of overall adverse events and AEs leading to discontinuation
To evaluate the safety and tolerability profile of 120 mcg BXCL501
Time frame: Through study completion, an average of 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2022 to primary completion in Aug 2025, 32 months.
Of 23 phase 3 interventional studies under Psychomotor Agitation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 47. This study's 32 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc